미만성 긴 병변이 있는 급성심근경색환자에서 긴 단일 용출 스텐트 시술과 중첩 스텐트 시술의 효과 비교 = Comparison of Efficacy of Overlapped Versus Long Eluting Stent in Acute Myocardial Infarction Patients with Diffuse Long Lesion

다국어 초록 (Multilingual Abstract)

The purpose of this study was to compare the outcomes of two interventional methods, overlapping drug-eluting stents (DES) and long DES, for long-term clinical outcomes in patients with acute myocardial infarction (AMI). A total of 438 patients with AMI (65.9±11.0 years, 306 males) from June 2008 to March 2019 who had diffuse long coronary artery lesion, more than 30mm were divided into two groups; group I (overlapped DES group; n=140) and group II (long DES group; n=298). We compared the incidences of major adverse cardiac events [MACEs; cardiac death, myocardial infaction (MI), target lesion revascularization (TLR) and stent thrombosis (ST)] during 12 months between the two groups. Everolimus-eluting stent was more commonly used in group II than in group I (28.1% vs. 51.8% p<0.001). Mean lesion diameter was slightly longer in group II (3.1±0.3mm vs. 3.2±0.3mm, p=0.042), and prevalence of ACC/AHA lesion type C was higher in group I (41.7% vs. 25.4%, p<0.001). Incidences of MACEs during 12 months were higher in group I than group II (18.5% vs. 14.4%, p=0.034). The rates of cardiac death (2.1% vs. 4.4%, p=0.667), MI (5.0% vs. 2.7%, p=0.260) and stent thrombosis rate (0.7% vs. 1.7%, p=0.669) were similar between the two groups. However, TLR rate was higher in group I (10.7% vs. 5.6%, p=0.041). In multivariate logistic regression analysis, presence of diabetes mellitus [Hazard ratio (HR) 2.383, 95% confidence interval (CI) 1.332–4.260, p=0.003] and use of paclitaxel-eluting stent (HR) 2.367, 95% CI 1.371–4.086, p=0.002) were independent predictors of 12-month MACEs, without significant differences in prevalence between the two groups. In AMI patients with diffuse long lesion, TLR rate was higher in the overlapped DES group during 12-month follow-up. Presence of diabetes and use of paclitaxel-eluting stent were independent predictors of MACEs.

국문 초록 (Abstract)

미만성 긴 병변이 있는 급성심근경색증 환자에서 장기적인 임상 결과에 대해 중첩된 약물용출스텐트와 긴 단일 약물용출스텐트라는 두 가지 중재 방법으로 시술한 환자의 관상동맥조영술 결과와 임상결과를 비교·분석하였다. 2008년 6월부터 2019년 3월까지 급성심근경색환자 (65.9±11.0세, 남성 306명)가 미만성 긴 관상동맥 병변 30 mm이상 병변에 대해서 두 그룹으로 나뉘었습니다. 그룹I (중첩 약물용출스텐트 그룹; n=140) 및 그룹II (긴 단일 약물용출스텐트 그룹; n=298). 주요심장사건의 발생률을 비교하였다[주요심장사건; 두 그룹 사이에서 12개월 동안 심장사망률, 심근경색, 표적병변 재개통술 및 스텐트 혈전증]. Everolimus-용출 스텐트는 그룹I보다 그룹II에서 더 일반적으로 사용되었고(28.1% vs. 51.8% p<0.001), 시술 전 평균 병변 직경은 그룹II에서 약간 굵었고 (3.1±0.3mm vs. 3.2±0.3mm, p=0.042), ACC / AHA 병변 유형C의 유병률은 그룹I에서 더 높았다(41.7% vs. 25.4%, p<0.001). 12개월 동안 주요심장사건의 발생률은 그룹II보다 그룹I에서 더 높았고(18.5% vs. 14.4%, p=0.034), 심장 사망률 (2.1% vs. 4.4%, p=0.667), 심근경색 (5.0% vs. 2.7%, p=0.260) 및 스텐트 혈전증률 (0.7% vs. 1.7%, p=0.669)은 두 그룹 차이가 없었다. 그러나 표적병변 재개통술 비율은 그룹I에서 더 높았다(10.7% vs. 5.6%, p=0.041). 다변량 로지스틱 회귀 분석에서 당뇨병의 존재[위험률 2.383, 95 % 신뢰 구간 1.332–4.260, p=0.003]과 파클리탁셀-용출 스텐트[위험률 2.367, 95 % 신뢰 구간 1.371–4.086), p=0.002]는 12개월 주요심장사건의 독립적 예측인자였으며, 두 그룹 사이의 유병률에 큰 차이가 없었다.
미만성 병변이 있는 급성심근경색 환자에서 12개월의 추적 관찰 기간 동안 중첩 약물용출스텐트 그룹에서 표적병변 재개통술 비율이 더 높았고 당뇨병의 존재 및 파클리탁셀-용출 스텐트의 사용은 주요심장사건의 독립적인 예측인자였다.

참고문헌 (Reference)

1 김원, "미만성 관상동맥병변에 대한 약물 용출성스텐트 중첩 시술의 재협착 예방 효과" 대한심장학회 36 (36): 17-23, 2006

2 Muzaffer Degertekin, "Very long sirolimus-eluting stent implantation for de novo coronary lesions" Elsevier BV 93 (93): 826-829, 2004

3 M. Degertekin, "Very long sirolimus-eluting stent implantation for de novo coronary lesions" 93 : 826-829, 2004

4 Hiromasa Otake, "Vascular Response to Overlapping Everolimus-Eluting Stents - Comparison With Paclitaxel-Eluting Stents -" Japanese Circulation Society 74 (74): 1023-1025, 2010

5 Kang-Yin Chen, "Unrestricted Use of 2 New-Generation Drug-Eluting Stents in Patients With Acute Myocardial Infarction" Elsevier BV 5 (5): 936-945, 2012

6 Masahiro Natsuaki, "Two-Year Outcome of a Randomized Trial Comparing Second-Generation Drug-Eluting Stents Using Biodegradable or Durable Polymer" American Medical Association (AMA) 311 (311): 2125-2127, 2014

7 Miodrag Ostojic, "The pharmacokinetics of Biolimus A9 after elution from the Nobori stent in patients with coronary artery disease: The NOBORI PK study" Wiley 72 (72): 901-908, 2008

8 Hana Vaknin-Assa, "Stent thrombosis following drug-eluting stent implantation. A single-center experience" Elsevier BV 8 (8): 243-247, 2007

9 E. Regar, "Stent development and local drug delivery" 59 : 227-248, 2001

10 TANIA CHECHI, "Single-Center Randomized Evaluation of Paclitaxel-Eluting Versus Conventional Stent in Acute Myocardial Infarction (SELECTION)" Wiley 20 (20): 282-291, 2007

11 Sripal Bangalore, "Short- and Long-Term Outcomes With Drug-Eluting and Bare-Metal Coronary Stents" Ovid Technologies (Wolters Kluwer Health) 125 (125): 2873-2891, 2012

12 Mehdi H. Shishehbor, "Safety and efficacy of overlapping sirolimus-eluting versus paclitaxel-eluting stents" Elsevier BV 155 (155): 1075-1080, 2008

13 Khurshid Ahmed, "Safety and Efficacy of Overlapping Homogenous Drug-Eluting Stents in Patients with Acute Myocardial Infarction: Results from Korea Acute Myocardial Infarction Registry" 대한의학회 27 (27): 1339-1346, 2012

14 Ajay J. Kirtane, "Safety and Efficacy of Drug-Eluting and Bare Metal Stents" Ovid Technologies (Wolters Kluwer Health) 119 (119): 3198-3206, 2009

15 Hironori Kitabata, "Safety and Efficacy Outcomes of Overlapping Second-Generation Everolimus-Eluting Stents Versus First-Generation Drug-Eluting Stents" Elsevier BV 112 (112): 1093-1098, 2013

16 Herve Le Breton, "Role of Platelets in Restenosis After Percutaneous Coronary Revascularization" Elsevier BV 28 (28): 1643-1651, 1996

17 Patrick W. Serruys, "Percutaneous Coronary Intervention versus Coronary-Artery Bypass Grafting for Severe Coronary Artery Disease" Massachusetts Medical Society 360 (360): 961-972, 2009

18 Patrick W. Serruys, "Percutaneous Coronary Intervention versus Coronary-Artery Bypass Grafting for Severe Coronary Artery Disease" Massachusetts Medical Society 360 (360): 961-972, 2009

19 Christoph Stettler, "Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis" Elsevier BV 370 (370): 937-948, 2007

20 Andreas R. Grüntzig, "Nonoperative Dilatation of Coronary-Artery Stenosis" Massachusetts Medical Society 301 (301): 61-68, 1979

21 Paul C. Gordon, "Mechanisms of restenosis and redilation within coronary stents—Quantitative angiographic assessment" Elsevier BV 21 (21): 1166-1174, 1993

22 Giulio G Stefanini, "Long-term clinical outcomes of biodegradable polymer biolimus-eluting stents versus durable polymer sirolimus-eluting stents in patients with coronary artery disease (LEADERS): 4 year follow-up of a randomised non-inferiority trial" Elsevier BV 378 (378): 1940-1948, 2011

23 Stefan K. James, "Long-Term Safety and Efficacy of Drug-Eluting versus Bare-Metal Stents in Sweden" Massachusetts Medical Society 360 (360): 1933-1945, 2009

24 Renu Virmani, "Localized Hypersensitivity and Late Coronary Thrombosis Secondary to a Sirolimus-Eluting Stent" Ovid Technologies (Wolters Kluwer Health) 109 (109): 701-705, 2004

25 Sang Yup Lim, "Inflammation and Delayed Endothelization With Overlapping Drug-Eluting Stents in a Porcine Model of In-Stent Restenosis" Japanese Circulation Society 72 (72): 463-468, 2008

26 Ioannis Iakovou, "Incidence, Predictors, and Outcome of Thrombosis After Successful Implantation of Drug-Eluting Stents" American Medical Association (AMA) 293 (293): 2126-, 2005

27 C. J. O’Sullivan, "Impact of stent overlap on long-term clinical outcomes in patients treated with newer-generation drug-eluting stents" 9 : 1076-1084, 2004

28 Vasim Farooq, "Impact of overlapping newer generation drug-eluting stents on clinical and angiographic outcomes: pooled analysis of five trials from the international Global RESOLUTE Program" BMJ 99 (99): 626-633, 2013

29 Lorenz Räber, "Impact of Stent Overlap on Angiographic and Long-Term Clinical Outcome in Patients Undergoing Drug-Eluting Stent Implantation" Elsevier BV 55 (55): 1178-1188, 2010

30 Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology(ESC), "ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation" 33 : 2569-2619, 2012

31 A. Messori, "Drug-eluting stents for the treatment of coronary artery disease : NICE technology appraisal guidance" 95 : 84-, 2009

32 Aloke V. Finn, "Differential Response of Delayed Healing and Persistent Inflammation at Sites of Overlapping Sirolimus- or Paclitaxel-Eluting Stents" Ovid Technologies (Wolters Kluwer Health) 112 (112): 270-278, 2005

33 Aloke V. Finn, "Differential Response of Delayed Healing and Persistent Inflammation at Sites of Overlapping Sirolimus- or Paclitaxel-Eluting Stents" Ovid Technologies (Wolters Kluwer Health) 112 (112): 270-278, 2005

34 N. Mori, "Different neointimal response to overlapping segments between everolimus-eluting stents and sirolimus-eluting stents-optical coherence tomographic study" 124 : A12546-, 2011

35 Pramod K. Kuchulakanti, "Correlates and Long-Term Outcomes of Angiographically Proven Stent Thrombosis With Sirolimus- and Paclitaxel-Eluting Stents" Ovid Technologies (Wolters Kluwer Health) 113 (113): 1108-1113, 2006

36 Khurshid Ahmed, "Comparison of zotarolimus- and everolimus-eluting stents in patients with ST-elevation myocardial infarction and chronic kidney disease undergoing primary percutaneous coronary intervention" Elsevier BV 64 (64): 273-278, 2014

37 Patrick W. Serruys, "Comparison of Zotarolimus-Eluting and Everolimus-Eluting Coronary Stents" Massachusetts Medical Society 363 (363): 136-146, 2010

38 Naoki Mori, "Comparison of Angiographic and 1-Year Outcomes Between a Long Single Stent and Overlapping Double Stents in Patients With Newer-Generation Drug-Eluting Stents for Long Narrowings" Elsevier BV 117 (117): 1724-1728, 2016

39 Keith D. Dawkins, "Clinical Efficacy of Polymer-Based Paclitaxel-Eluting Stents in the Treatment of Complex, Long Coronary Artery Lesions From a Multicenter, Randomized Trial" Ovid Technologies (Wolters Kluwer Health) 112 (112): 3306-3313, 2005

40 Hiroshi Doi, "Classification and Potential Mechanisms of Intravascular Ultrasound Patterns of Stent Fracture" Elsevier BV 103 (103): 818-823, 2009

41 Stephan Windecker, "Biolimus-eluting stent with biodegradable polymer versus sirolimus-eluting stent with durable polymer for coronary revascularisation (LEADERS): a randomised non-inferiority trial" Elsevier BV 372 (372): 1163-1173, 2008

42 Xiao-Fang Tang, "Biodegradable polymer drug-eluting stents versus second-generation drug-eluting stents in patients with and without diabetes mellitus: a single-center study" Springer Science and Business Media LLC 17 (17): 114-, 2018

43 G. G. Stefanini, "Biodegradable polymer drug-eluting stents reduce the risk of stent thrombosis at 4 years in patients undergoing percutaneous coronary intervention : a pooled analysis of individual patient data from the ISAR-TEST 3, ISAR-TEST 4, and LEADERS randomized trials" 33 : 1214-1222, 2012

44 Eberhard Grube, "BioMatrix Biolimus A9-eluting coronary stent: a next-generation drug-eluting stent for coronary artery disease" Informa UK Limited 3 (3): 731-741, 2014

45 David R. Holmes, "Analysis of 1-Year Clinical Outcomes in the SIRIUS Trial" Ovid Technologies (Wolters Kluwer Health) 109 (109): 634-640, 2004

46 Babak Azarbal, "Allergic Reactions After the Implantation of Drug-Eluting Stents" Elsevier BV 47 (47): 182-183, 2006

47 Patrick W. Serruys, "A randomized comparison of the value of additional stenting after optimal balloon angioplasty for long coronary lesions" Elsevier BV 39 (39): 393-399, 2002

48 David L. Fischman, "A Randomized Comparison of Coronary-Stent Placement and Balloon Angioplasty in the Treatment of Coronary Artery Disease" Massachusetts Medical Society 331 (331): 496-501, 1994

49 Seung-Jung Park, "A Paclitaxel-Eluting Stent for the Prevention of Coronary Restenosis" Massachusetts Medical Society 348 (348): 1537-1545, 2003

50 Patrick W. Serruys, "A Comparison of Balloon-Expandable-Stent Implantation with Balloon Angioplasty in Patients with Coronary Artery Disease" Massachusetts Medical Society 331 (331): 489-495, 1994

51 Spencer B. King, "2007 Focused Update of the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention" Ovid Technologies (Wolters Kluwer Health) 117 (117): 261-295, 2008

52 Anne Kaltoft, "2-Year Clinical Outcomes After Implantation of Sirolimus-Eluting, Paclitaxel-Eluting, and Bare-Metal Coronary Stents" Elsevier BV 53 (53): 658-664, 2009